FIELD: medicine.
SUBSTANCE: invention relates to stable compositions for intrathecal or intracerebroventricular administration for the treatment of Hunter syndrome, which contain protein of iduronate-2-sulphatase (I2S) in a concentration from 5 to 150 mg/ml and no more than 50 mM of phosphate with pH of 5.5-7.0.
EFFECT: obtaining methods and compositions for the delivery of iduronate-2-sulphatase to the CNS.
41 cl, 64 dwg, 27 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF IDURONATE-2-SULFATASE | 2011 |
|
RU2660348C2 |
| MEDICAL AGENTS DELIVERY TO THE CENTRAL NERVOUS SYSTEM | 2011 |
|
RU2626514C2 |
| THERAPEUTIC TARGETED FUSION PROTEINS BASED ON LYSOSOMAL ENZYMES, RELEVANT COMPOSITIONS AND THEIR APPLICATIONS | 2017 |
|
RU2751235C2 |
| METHODS AND COMPOSITIONS FOR DELIVERY OF ARYLSULFATASE A TO CNS | 2011 |
|
RU2783380C2 |
| METHODS AND COMPOSITIONS FOR CNS DELIVERY OF ARYLSULFATASE A | 2011 |
|
RU2671503C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| COMPOUND CONTAINING THERAPEUTIC ENZYME AND TRANSPORT ELEMENT CONNECTED TO EACH OTHER DIRECTLY OR BY USING LINKER | 2022 |
|
RU2811100C1 |
| METHODS AND COMPOSITIONS FOR DELIVERING THERAPEUTIC PROTEIN | 2019 |
|
RU2818779C2 |
| TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOF | 2013 |
|
RU2680581C2 |
| VECTOR BASED ON ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | 2016 |
|
RU2804953C2 |
